JFS Wealth Advisors LLC Sells 25,865 Shares of GSK plc (NYSE:GSK)

JFS Wealth Advisors LLC lowered its stake in shares of GSK plc (NYSE:GSK - Free Report) by 87.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,561 shares of the pharmaceutical company's stock after selling 25,865 shares during the quarter. JFS Wealth Advisors LLC's holdings in GSK were worth $120,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Indiana Trust & Investment Management Co boosted its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Eastern Bank bought a new position in shares of GSK in the 3rd quarter valued at about $26,000. Crews Bank & Trust bought a new position in shares of GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its stake in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Finally, Sunbelt Securities Inc. raised its position in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares during the period. Institutional investors own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GSK shares. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and cut their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Stock Down 0.9 %

GSK stock traded down $0.34 during mid-day trading on Friday, hitting $36.62. 5,644,657 shares of the company were exchanged, compared to its average volume of 4,666,008. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a market cap of $75.91 billion, a P/E ratio of 23.03, a P/E/G ratio of 1.11 and a beta of 0.64. The firm's 50 day simple moving average is $34.61 and its 200 day simple moving average is $37.36. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, sell-side analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.29%. The ex-dividend date of this dividend is Friday, February 21st. GSK's dividend payout ratio (DPR) is currently 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.